Navigation Links
Moffitt Cancer Center researchers unravel biochemical factor important in tumor metastasis
Date:11/9/2011

TAMPA, Fla. -- A protein called "fascin" appears to play a critical transformation role in TGF beta mediated tumor metastasis, say researchers at Moffitt Cancer Center in Tampa, Fla., who published a study in a recent issue of the Journal of Biological Chemistry.

According to study corresponding author Shengyu Yang, Ph.D., of Moffitt's Comprehensive Melanoma Research Center and the Department of Tumor Biology, elevated Transforming Growth Factor beta in the tumor microenvironment may be responsible for fascin over-expression, which in turn can promote metastasis in some metastatic tumors.

TGF beta is a versatile cytokine involved in many physiological and pathological processes in adults and in the developing embryo, including cell growth, cell differentiation, cell death (apoptosis) and cellular homeostasis. TGF beta is best known as a tumor suppressor, exerting growth inhibitory roles in normal tissue and early stage tumors. However, many metastatic tumors are able to overcome the growth inhibition and secreted elevated levels of TGF beta to promote tumor metastasis. How TGF beta promotes metastasis is not completely understood. The authors suggested that fascin may be the key to understand the pro-metastasis function of TGF beta, as fascin knockdown almost completely abolished TGF beta induced tumor cell migration and invasion.

The researchers explained that fascin levels are low or not detected in normal tissues, but are highly elevated in malignant tumors. Also, high fascin expression is associated with poor prognosis. It has been clear for some time, they noted, that there is a causal role for fascin over-expression in tumor cell dissemination. However, the underlying mechanism for the elevation of fascin levels has not been clarified. Their analysis using cell culture- based assay and patient microarray data mining strongly suggests that elevated TGF beta levels in tumors lead to fascin overexpression, which in turn promotes metastasis.

"Our data suggests that fascin is an immediate TGF beta target gene essential for its pro-invasion activity in cancer metastasis," explained Yang.

While there have been many studies on the role of fascin in tumor cell migration and metastasis, the current study is first to report that TGF beta elevates fascin protein expression to promote invasion, particularly in tumor cells of spindle-shaped the kind of morphology associated with high tumor invasiveness and more metastatic disease.

"The finding that TGF beta only induces fascin over-expression in highly metastatic tumor cells is especially interesting," said Yang. "Therapies targeting fascin may block TGF beta mediated metastasis without interfering with the tumor suppressor role of TGF beta in normal tissues."


'/>"/>
Contact: Ferdie De Vega
Ferdinand.DeVega@moffitt.org
813-745-7858
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
2. Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
3. Moffitt Cancer Center researchers use new tool to counter multiple myeloma drug resistance
4. Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer
5. Moffitt Cancer Center researchers find more clues to causes of breast cancer
6. Moffitt Cancer Center researchers find regulatory T-cell clue to help prevent GVHD
7. Enhancing arrest of cell growth to treat cancer in mice
8. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
9. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
10. Low forms of cyclin E reduce breast cancer drugs effectiveness
11. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob ... sciatica in a new episode of "Success Files," which is an award-winning educational ... and investigates each subject in-depth with passion and integrity. , Sciatica occurs when ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... Fla. (PRWEB) , ... October 12, 2017 , ... IsoComforter, ... therapy products, announced today the introduction of an innovative new design of the shoulder ... pad so you get maximum comfort while controlling your pain while using cold therapy. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
(Date:9/19/2017)... Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, ... tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , PhD, ...
Breaking Medicine Technology: